Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1936-0541
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B ; day:24 ; month:10 ; year:2020 ; pages:1-12
Hepatology international ; (24.10.2020), 1-12
- Urheber
-
Huang, Yi-Wen
Hsu, Chao-Wei
Lu, Sheng-Nan
Yu, Ming-Lung
Su, Chien-Wei
Su, Wei-Wen
Chien, Rong-Nan
Hsu, Ching-Sheng
Hsu, Shih-Jer
Lai, Hsueh-Chou
Qin, Albert
Tseng, Kuan-Chiao
Chen, Pei-Jer
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12072-020-10098-y
- URN
-
urn:nbn:de:101:1-2020121001224296114819
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Huang, Yi-Wen
- Hsu, Chao-Wei
- Lu, Sheng-Nan
- Yu, Ming-Lung
- Su, Chien-Wei
- Su, Wei-Wen
- Chien, Rong-Nan
- Hsu, Ching-Sheng
- Hsu, Shih-Jer
- Lai, Hsueh-Chou
- Qin, Albert
- Tseng, Kuan-Chiao
- Chen, Pei-Jer
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks
Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2
Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
Zur Behandlung der Haarzell-Leukämie mit rekombinantem Interferon alfa-2b
Ropeginterferon alfa-2b (Polycythaemia vera) : Nutzenbewertung gemäß § 35a SGB V
α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alfa-2b
PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system
Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
Safety evaluation of PEGylated MNPs and p-PEGylated MNPs in SD rats
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks
Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2
Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
Zur Behandlung der Haarzell-Leukämie mit rekombinantem Interferon alfa-2b
Ropeginterferon alfa-2b (Polycythaemia vera) : Nutzenbewertung gemäß § 35a SGB V
α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alfa-2b
PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system
Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
Safety evaluation of PEGylated MNPs and p-PEGylated MNPs in SD rats
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks
Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2
Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
Zur Behandlung der Haarzell-Leukämie mit rekombinantem Interferon alfa-2b
Ropeginterferon alfa-2b (Polycythaemia vera) : Nutzenbewertung gemäß § 35a SGB V
α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alfa-2b
PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system
Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
Safety evaluation of PEGylated MNPs and p-PEGylated MNPs in SD rats